Navigation Links
SPO Reports Results for Second Quarter 2013
Date:8/20/2013

NEW YORK, August 20, 2013 /PRNewswire/ --

SPO (SPOM), a leading developer of biosensor and microprocessor technologies for use in portable monitoring devices, announced recently its financial results for the fiscal quarter ended June 30, 2013.

Total revenue for first half 2013 was $249,000 compared to no revenues for the same period in 2012. In addition the Company has a current backlog of approximately $249,000 of purchase orders which it intends to deliver during 3rd quarter 2013. The revenue increase was attributed to shipments of our new consumer wellness product to mass market retailers. Since August 2012, we have partnered with HoMedics LLC for distribution of our private-labeled pulse oximeter known as the HoMedics Deluxe Pulse Oximeter.

Furthermore, the Company announced that it has commenced commercialization of its new consumer wellness time-piece designed to measure overall daily activity levels, especially useful for the estimated 100 million obese adults & children in the US. The Company is working closely with its distribution partner to realize this retail opportunity commencing late 2013 and beyond.

Michael Braunold, Chief Executive Officer of SPO commented: "We are pleased with our continuing success, working with our partners HoMedics for retail distribution of our private-labeled pulse oximeter. Our new wellness watch will also be available for sale shortly, and we look forward to capitalizing on both these revenue opportunities in the coming quarters and into 2014. Adding this second product to our portfolio in a relatively short period of time has allowed us to further expand our strategy in the fast-growing consumer wellness market. In addition, we continue to work on other product opportunities, including a unique baby-monitor for parental reassurance when babies are sleeping and a sports watch to continuously measure heart-rate during exercise without the need of a chest strap."

The new wellness time-piece, designed both for children and adults, has innovative features including display functionality and a time-piece which continuously measures number of daily movements and calories burned against preset recommended goals. Furthermore, the watch is designed to encourage individuals to wear it with pride and to help towards improving their overall lifestyle.

Further details as to SPO's financial information and results of operations for the fiscal quarter ended June 30, 2013 are in the Company's Quarterly Report on Form 10-Q filed with the Securities and Exchange Commission on August 8, 2013.

About SPO

SPO is a leading developer of biosensor and microprocessor technologies for use in portable monitoring devices to capture life-enhancing information within four key markets: medical care; sports and wellness; homecare monitoring and security. Its patented technology uses information gathered from the reflectance of light on the human body, in a noninvasive manner, to monitor key vital signs. The company manufactures its products in addition to licensing its technologies to appropriate client corporations for commercialization and distribution. For more information, visit http://www.spoglobal.com

Forward Looking Statements

This press release contains forward-looking statements that involve substantial uncertainties and risks. These forward-looking statements are based upon our current expectations, estimates and projections about our business and our industry, and that reflect our beliefs and assumptions based upon information available to us at the date of this release. We caution readers that forward looking statements are predictions based on our current expectations about future events. These forward-looking statements are not guarantees of future performance and are subject to risks, uncertainties and assumptions that are difficult to predict. Our actual results, performance or achievements could differ materially from those expressed or implied by the forward-looking statements as a result of a number of factors, including but not limited to, expectations as to the realization of additional revenues from the order backlog, expectations as to the timing and the commercial launch of our new consumer wellness timepiece as well as our efforts to expand distribution of products to additional mass market retailers, the ability to create additional strategic partnerships to aid in the distribution of products, expectations regarding the successful expansion of our product base to include, among other products, the baby monitor and the sports watch, profitability, market acceptance of our products and new product applications, timing of new product launches, success of the Company's rebranding program, product performance, size of prospective markets, revenue assessments, marketing strategies, success of our restructured operations and plans, our ability to generate fees or raise capital to support our business operations and plan, the sufficiency and availability of working capital, changes in economic conditions generally and in more specifically, the introduction of competing products, changes in our operating strategy or development plans patent protection for our products and technologies, changes in economic conditions generally and in more specifically, in the markets we operate, changes in technology, legislative or regulatory changes that affect us and the risks and uncertainties discussed under the heading "Risk Factors" in Item 1 of our Annual Report on Form 10-K for the fiscal year ended December 31, 2012. We undertake no obligation to revise or update any forward-looking statement for any reason.

Contact regarding this release:
SPO
investors@spoglobal.com
+1-866-991-7766


'/>"/>
SOURCE SPO Medical
Copyright©2012 PR Newswire.
All rights reserved

Related biology technology :

1. Global IVIG Market Report 2013 Edition Research at MarketReportsOnline.com
2. Cellular Biomedicine Group Reports Second Quarter and First Half 2013 Financial Results and Business Highlights
3. AML Therapeutics Market in the 6MM Worth $430.7m in 2017 Says a New Research Report Available at ReportsnReports.com
4. Synthetic Biologics Reports Second Quarter 2013 Financial Results and Operational Update
5. Intercept Pharmaceuticals Reports Second Quarter 2013 Financial Results
6. Organovo Reports Q1 Fiscal 2014 Results, Provides Business Update
7. Dyadic International Reports Second Quarter 2013 Financial Results
8. Microbes Market and Microbial Products Reviewed in New Research Report at ReportsnReports.com
9. Discovery Labs Reports Second Quarter 2013 Financial Results
10. Global Crop Protection Chemicals Market Till 2016 - Worldwide Research Report, Industry Share, Size, Trends, Analysis, Growth and Forecast 2012-2016: MarketResearchReports
11. Z Trim Holdings Reports Sales Growth in July 2013 over July 2012
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/22/2016)... ... June 22, 2016 , ... Quantitative ... business incubator and current participant in the Phase 1 Ventures program, is leveraging ... , Quantitative Radiology Solutions helps physicians make better treatment decisions by quantifying ...
(Date:6/22/2016)... (PRWEB) , ... June 21, 2016 , ... New light-based ... cutting into the tissue — promise to enable both compact, wearable devices for point-of-care ... even deeper under the skin. , Recent work and visionary future directions are detailed ...
(Date:6/22/2016)... SAN DIEGO , June 22, 2016 /PRNewswire/ ... that has developed a testing platform designed specifically ... the formation of their scientific advisory board (SAB). ... of directors, the SAB is chartered to advise ... infectious disease assay platform. Led by Dr. ...
(Date:6/22/2016)... June 22, 2016 On Tuesday, June ... 4,843.76, up 0.14%; the Dow Jones Industrial Average advanced 0.14% ... 2,088.90, up 0.27%. The gains were broad based as five ... has initiated coverage on the following equities: Minerva Neurosciences Inc. ... PTLA ), Trevena Inc. (NASDAQ: TRVN ), ...
Breaking Biology Technology:
(Date:4/28/2016)... First quarter 2016:   , ... the first quarter of 2015 The gross margin was ... 18.8) and the operating margin was 40% (-13) Earnings ... flow from operations was SEK 249.9 M (21.2) , ... SEK 7,000-8,500 M. The operating margin for 2016 is ...
(Date:4/19/2016)... 2016 The new GEZE SecuLogic ... web-based "all-in-one" system solution for all door components. It ... the door interface with integration authorization management system, and ... The minimal dimensions of the access control and the ... installations offer considerable freedom of design with regard to ...
(Date:4/14/2016)... BioCatch ™, the global ... the appointment of Eyal Goldwerger as CEO. ... Goldwerger,s leadership appointment comes at a time of significant ... of its platform at several of the world,s largest ... unique cognitive and physiological factors, is a winner of ...
Breaking Biology News(10 mins):